Insights

Innovative Oncology Focus Enzyme by Design specializes in developing targeted biologics for difficult-to-treat cancers like acute myeloid leukemia and pancreatic tumors, presenting opportunities to offer advanced protein engineering solutions and customized biologic platforms to biotech and pharmaceutical companies.

Strategic Partnerships The company's partnership with Halo Cures indicates an openness to collaboration, creating potential for joint ventures, licensing arrangements, or co-development opportunities with other biotech firms seeking innovative cancer therapies.

Funding and Growth Having secured approximately 1 million dollars through grants and research funding highlights early-stage growth and validates their research approach, providing openings for investors and funding partners interested in innovative biotech startups.

Technology and Research Capabilities Enzyme by Design's expertise in protein engineering and its focus on genomics-driven patient stratification suggest opportunities to supply or integrate advanced biotech tools, reagents, or custom protein design services with major research and development organizations.

Market Expansion Potential With revenue estimated between 1 million and 10 million dollars and a focus on high-impact cancer treatments, the company is positioned for growth, signaling potential for commercial partnerships, distribution channels, and licensing deals in the oncology therapeutics market.

Enzyme by Design Tech Stack

Enzyme by Design uses 8 technology products and services including Open Graph, Google Workspace, MyWebsite, and more. Explore Enzyme by Design's tech stack below.

  • Open Graph
    Content Management System
  • Google Workspace
    Email
  • MyWebsite
    Page Builders
  • MyWebsite Creator
    Page Builders
  • X-XSS-Protection
    Security
  • X-Content-Type-Options
    Web & Portal Technology
  • Apache HTTP Server
    Web Servers
  • Apache
    Web Servers

Enzyme by Design's Email Address Formats

Enzyme by Design uses at least 1 format(s):
Enzyme by Design Email FormatsExamplePercentage
First.Last@enzymebydesign.comJohn.Doe@enzymebydesign.com
36%
First@enzymebydesign.comJohn@enzymebydesign.com
14%
First.Last@enzymebydesign.comJohn.Doe@enzymebydesign.com
36%
First@enzymebydesign.comJohn@enzymebydesign.com
14%

Frequently Asked Questions

Where is Enzyme by Design's headquarters located?

Minus sign iconPlus sign icon
Enzyme by Design's main headquarters is located at Chicago, Illinois 60612 United States. The company has employees across 2 continents, including North AmericaEurope.

What is Enzyme by Design's official website and social media links?

Minus sign iconPlus sign icon
Enzyme by Design's official website is enzymebydesign.com and has social profiles on LinkedIn.

What is Enzyme by Design's SIC code NAICS code?

Minus sign iconPlus sign icon
Enzyme by Design's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Enzyme by Design have currently?

Minus sign iconPlus sign icon
As of April 2026, Enzyme by Design has approximately 4 employees across 2 continents, including North AmericaEurope. Key team members include Chief Operating Officer: A. S.Owner: P. D. P.Treasurer: L. P.. Explore Enzyme by Design's employee directory with LeadIQ.

What industry does Enzyme by Design belong to?

Minus sign iconPlus sign icon
Enzyme by Design operates in the Biotechnology Research industry.

What technology does Enzyme by Design use?

Minus sign iconPlus sign icon
Enzyme by Design's tech stack includes Open GraphGoogle WorkspaceMyWebsiteMyWebsite CreatorX-XSS-ProtectionX-Content-Type-OptionsApache HTTP ServerApache.

What is Enzyme by Design's email format?

Minus sign iconPlus sign icon
Enzyme by Design's email format typically follows the pattern of First.Last@enzymebydesign.com. Find more Enzyme by Design email formats with LeadIQ.

Enzyme by Design

Biotechnology ResearchIllinois, United States2-10 Employees

Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at exploiting weaknesses in cancers and eradicating tumor cells but with a clear focus on patient safety and reducing side effects. In this way, we can both treat the disease and improve patient quality of life and outcomes. We have used our core expertise of protein engineering to create protein molecules that target the most common pediatric cancer as well as infamously difficult to treat cancers like acute myeloid leukemia and the solid tumors pancreatic, liver, and ovarian cancers. Utilizing well-known drug mechanisms of action and patient genomic and epigenetic markers will guide our clinical strategy as we move forward to make sure that only patients likely to benefit greatly from our biologics will be receiving them. The time is now for better cancer treatment options.

Section iconCompany Overview

Headquarters
Chicago, Illinois 60612 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $1M$10M

    Enzyme by Design's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Enzyme by Design's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.